2025
Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.
Gupta S, Grivas P, Park S, Petrylak D, Tyroller K, Hoffman J, Bellmunt J. Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100. Journal Of Clinical Oncology 2025, 43: 869-869. DOI: 10.1200/jco.2025.43.5_suppl.869.Peer-Reviewed Original ResearchProgression-free survivalAdvanced urothelial carcinomaBest supportive carePlatinum-based chemotherapyOverall survivalDiabetes mellitusAdverse eventsAssociated with long-term efficacyImmune-related adverse eventsTreatment-related adverse eventsFirst-line maintenanceAssociated with reduced efficacyEfficacy of immunotherapyMedian Follow-UpProlonged overall survivalLong-term efficacyPresence of DMLong-term outcomesPost hoc exploratory analysisJAVELIN BladderMedian OSMetastatic UCUrothelial carcinomaEligible ptsPrimary endpoint
2020
Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study.
Dutt R, Meagher M, Patil D, Saito K, Patel D, Ghali F, Keiner C, Miller N, Bradshaw A, Wan F, Yasuda Y, Fujii Y, Master V, Derweesh I. Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study. Journal Of Clinical Oncology 2020, 38: 666-666. DOI: 10.1200/jco.2020.38.6_suppl.666.Peer-Reviewed Original ResearchRenal cell carcinomaIndependent risk factorChronic kidney diseaseKaplan-Meier analysisRadical nephrectomyMultivariable analysisPartial nephrectomyRisk factorsPresence of DMFunctional declineDM statusOverall survivalKidney functionRCC patientsTumor sizeCell carcinomaRenal functional declineAfrican American raceInternational multicenter studyEffects of DMNDM patientsRN patientsCause mortalityWorse OSDiabetes mellitus
2016
Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus Insights From the PROSPECT Study
Kedhi E, Kennedy MW, Maehara A, Lansky AJ, McAndrew TC, Marso SP, De Bruyne B, Serruys PW, Stone GW. Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus Insights From the PROSPECT Study. JACC Cardiovascular Imaging 2016, 10: 451-458. PMID: 27372016, DOI: 10.1016/j.jcmg.2015.12.023.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDiabetes MellitusDisease ProgressionFemaleFibrosisHumansMaleMiddle AgedPercutaneous Coronary InterventionPlaque, AtheroscleroticPredictive Value of TestsPropensity ScoreRisk FactorsRupture, SpontaneousTime FactorsTreatment OutcomeUltrasonography, InterventionalConceptsMajor adverse cardiac eventsAcute coronary syndromeThin-cap fibroatheromaNonculprit lesionsDiabetes mellitusACS patientsDM patientsSubsequent major adverse cardiac eventsPresence of DMPROSPECT studyAdverse cardiac eventsPropensity-matched groupsRadiofrequency intravascular ultrasoundHigh rateCoronary syndromeCardiac eventsPlaque compositionIntravascular ultrasoundPatientsPropensity scoreBalanced groupsIschemicMellitusFibroatheromaPrognosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply